Folitixorin
(Synonyms: 5,10-亚甲基四氢叶酸(非对映体混合物),5,10-Methylenetetrafolate; ANX-510 free acid) 目录号 : GC49126
A reduced form of folate and cofactor for thymidylate synthetase
Cas No.:3432-99-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >82.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Folitixorin is a reduced form of folate and cofactor for thymidylate synthetase, the enzyme that catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).1,2 It forms a ternary complex with thymidylate synthetase and fluorodeoxyuridylate (FdUMP), the active metabolite of 5-fluorouracil , that inhibits thymidylate synthetase activity and DNA synthesis.3,2 Folitixorin has synergistic or additive cytotoxic effects against LS 174 or HT-29 human colon cancer cells, respectively, when used in combination with 5-fluorouracil.4 In vivo, folitixorin (0.6 mg/animal) increases survival and reduces tumor growth in an HT-29 mouse xenograft model when administered in combination with 5-fluorouracil.5
1.Zarow, C., Pellino, A.M., and Danenberg, P.V.Large-scale and small-scale methods for the preparation of 5,10-methylenetetrahydrofolatePrep. Biochem.12(5)381-393(1982) 2.Shirasaka, T., Shimamoto, Y., Ohshimo, H., et al.Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivoCancer Chemother. Pharmacol.32(3)167-172(1993) 3.Patel, K., Yerram, S.R., Azad, N.A., et al.A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosingOncotarget3(7)678-685(2012) 4.Bjelogrli?, S.K., Srdi?, T., and Radulovi?, S.Comparison between cofactor and leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell linesJ. BUON12(1)71-76(2007) 5.Cantwell, M.J., Spears, C.P., and Robbiins, J.M.Antitumor activity of combination 5,10-methylenetetrahydrofolate, 5-fluorouracil, and anti-vascular endothelial growth factor against human colorectal HT-29 tumors in nude miceJ. Clin. Oncol.22(14_suppl)3768(2004)
| Cas No. | 3432-99-3 | SDF | |
| 别名 | 5,10-亚甲基四氢叶酸(非对映体混合物),5,10-Methylenetetrafolate; ANX-510 free acid | ||
| Canonical SMILES | O=C1C2=C(NC(N)=N1)NCC3N2CN(C4=CC=C(C=C4)C(N[C@H](C(O)=O)CCC(O)=O)=O)C3 | ||
| 分子式 | C20H23N7O6 | 分子量 | 457.4 |
| 溶解度 | DMSO: slightly soluble | 储存条件 | -80°C,protect from light,stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1863 mL | 10.9314 mL | 21.8627 mL |
| 5 mM | 0.4373 mL | 2.1863 mL | 4.3725 mL |
| 10 mM | 0.2186 mL | 1.0931 mL | 2.1863 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。